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Abstract: Previous large-scale genetic studies identified single nucleotide polymorphisms (SNPs) of
the TM6SF2 and MBOAT7 genes as risk factors for alcoholic liver cirrhosis and non-alcoholic fatty
liver disease. In this study, we tried to evaluate the association between TM6SF2 variant rs58542926
and MBOAT7 variant rs641738 and the risk of hepatic fibrosis or liver cirrhosis of different etiology.
In parallel, we also aimed to evaluate whether these two SNPs modify the effects of the PNPLA3
rs738409 risk variant for the development of hepatic fibrosis and liver cirrhosis. The study was
conducted at the Department of Gastroenterology, Lithuanian University of Health Sciences Hospital,
and included 334 patients with liver cirrhosis, 128 patients with liver fibrosis, and 550 controls. SNPs
were genotyped by quantitative PCR, using TaqMan allelic discrimination assays. Overall, TM6SF2
rs58542926 as well as MBOAT7 rs641738 were not linked to hepatic fibrosis, alcohol or hepatitis C
virus induced liver cirrhosis in an Eastern European population. These genetic variations also did
not mediate the effect of PNPLA3 rs738409 SNP for liver developing liver fibrosis or liver cirrhosis.
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1. Introduction
Liver cirrhosis is one of the dominant causes of global disease burden and is associated with
life threatening complications [1]. In 2016, liver cirrhosis accounted for almost 39 million disability
adjusted life years (DALYs), or 1.6% of global DALYs, and resulted in more than three million deaths
worldwide [2,3]. The most common causes of chronic liver injury are hepatitis C virus (HCV) and
hepatitis B virus (HBV) infections, alcohol misuse, non-alcoholic steatohepatitis, autoimmune hepatitis
and other conditions [4–6]. To date, individual variability for susceptibility and severity of liver injury
is still not completely understood. An increasing burden of liver diseases, high individual variations
in disease course and rapidly developing genotyping technologies lead to multiple genetic studies
that showed the importance of genetic factors in the development and progression of chronic liver
injury [7–9].
Genome wide association studies (GWAS) are now widely used to identify associations between
single nucleotide polymorphisms (SNPs) and the risk of different diseases employing next-generation
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sequencing based techniques. Over the last decade a significant number of GWAS have been performed
in the field of hepatology [10], revealing the genetic predisposition for primary biliary cholangitis,
primary sclerosing cholangitis, steatohepatitis and other liver diseases [7]. Several groups including
ours have previously shown that the patatin-like phospholipase domain containing 3 (PNPLA3)
gene SNP is linked with liver injury [11,12]. More recently, transmembrane 6 superfamily member
2 (TM6SF2) and membrane-bound O-acyltransferase domain-containing protein 7 (MBOAT7) gene
polymorphisms have been identified as risk factors for alcoholic liver cirrhosis [12]. TM6SF2 variant
rs58542926 has also been associated with an increased risk of developing advanced hepatic fibrosis and
cirrhosis in patients with non-alcoholic fatty liver disease (NAFLD) [13]. Furthermore, the MBOAT7
polymorphism rs641738 was associated with the severity of liver fibrosis in individuals with chronic
hepatitis C virus infection [14] and NAFLD [15]. In a recent study, MBOAT7 rs641738 SNP was also
reported as an independent predictor of severe liver steatosis in patients with chronic hepatitis C [16].
In this study we analyzed the association between TM6SF2 variant rs58542926 and MBOAT7
variant rs641738 and the risk of hepatic fibrosis or liver cirrhosis of different etiology in an Eastern
European patient cohort. Additionally, we also aimed to evaluate whether these two SNPs modify the
effects of the PNPLA3 rs738409 risk variant on the development of hepatic fibrosis and liver cirrhosis.
2. Results
2.1. Characteristics of Study Participants
Table 1 presents the demographic and clinical characteristics of the study group. The mean
age of patients with liver cirrhosis was 51.8 years, and they were significantly older (p < 0.001) than
patients with liver fibrosis and controls. Men were predominant in the liver fibrosis group (61.7%.
p < 0.05). The major cause of liver cirrhosis was alcohol, the second most common cause was chronic
HCV infection. In the liver fibrosis group, the most common cause of liver injury was HCV infection.
To eliminate the potential bias of differences in age and sex distribution among the groups, these
parameters were included as covariates in logistic regression analysis. The frequencies of alleles and
genotypes were in Hardy–Weinberg equilibrium for all SNPs analyzed (all p > 0.05).
Table 1. Characteristics of patients with liver cirrhosis, hepatic fibrosis and controls.
Liver Cirrhosis (n = 334) Liver Fibrosis (n = 128) Controls (n = 550) p Value
Age (mean ± SD), years 51.8 ± 13.2 47.2 ± 13.4 47.3 ± 9.0 <0.001
Gender, n (%)
Male 166 (48.3%) 79 (61.7%) 271 (49.3%) <0.05
Female 168 (51.7%) 49 (38.3%) 279 (50.7%)
Aetiology of liver disease, n (%)
Alcohol 171 (51.2%) 8 (6.25%)
HCV 120 (35.9%) 112 (87.5%)
Other causes 43 (12.9%) 8 (6.25%)
HBV 17 (5.1%) 5 (3.9%)
HCC 13 (3.9%)
Autoimmune 8 (3.9%) 3 (2.3%)
Hemochromatosis 4 (1.2%)
Wilson’s disease 1 (0.3%)
HBV—hepatitis B virus, HCV—hepatitis C virus, HCC—hepatocellular carcinoma.
2.2. TM6SF2 rs58542926 and MBOAT7 rs641738 SNPs
Allele and genotype distributions for the TMS6SF2 rs58542926 and MBOAT7 rs641738
polymorphisms in patients with different etiology of liver cirrhosis, hepatic fibrosis and the control
groups are presented in Tables 2 and 3. TM6SF2 rs58542926 allele frequencies in controls, patients with
hepatic fibrosis, liver cirrhosis, alcohol-induced and HCV-induced cirrhosis were: T allele 7.5%, 5.5%,
8.4%, 8.1% and 7.5%; C allele 92.6%, 94.5%, 91.6%, 91.8% and 92.5%, respectively. None of the TM6SF2
rs58542926 alleles or genotypes were linked with the risk of developing liver fibrosis or cirrhosis.
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MBOAT7 rs641738 SNP alleles and genotypes showed similar distributions across all four groups of
the study. In controls, the frequencies of T and C alleles were 43.3% and 56.7%, in the liver fibrosis
group 41.4% and 58.6%, in the cirrhosis group 44.6% and 55.4%, in alcohol-induced cirrhosis 42.1%
and 57.9%, in HCV-induced cirrhosis 45.8% and 54.2%, and in patients with cirrhosis due to other
causes 51.2% and 48.8%, respectively. No significant differences between MBOAT7 rs641738 alleles
and genotypes among the different study groups were observed.





(n = 550) Fibrosis (n = 128) Cirrhosis (n = 334)
n (%) n (%) aOR (95% CI) p n (%) aOR (95% CI) p
rs58542926 (TM6SF2)
T 41 (7.45) 7 (5.47) 0.67 (0.37–1.23) 0.19 28 (8.38) 1.18 (0.83–1.68) 0.36
C 509 (92.55) 121 (94.53) 306 (91.62)
TT 2 (0.36) 0 (0) 0.81 (0.04–16.98) 0.48 2 (0.60) 1.69 (0.24–12.09) 0.59
TC 77 (14.0) 13 (10.16) 0.69 (0.37–1.28) 0.23 53 (15.87) 1.17 (0.80–1.71) 0.43
CC 471 (85.64) 115 (89.84) 1 (Reference) 279 (83.53) 1 (Reference)
rs641738 (MBOAT7)
T 238 (43.27) 53 (41.41) 0.94 (0.71–1.24) 0.65 149 (44.61) 1.05 (0.87–1.28) 0.61
C 312 (56.73) 75 (58.59) 185 (55.39)
TT 108 (19.64) 20 (15.63) 0.79 (0.45–1.43) 0.44 69 (20.66) 1.10 (0.75–1.62) 0.62
TC 261 (47.45) 66 (51.56) 1.11 (0.72–1.70) 0.65 160 (47.90) 1.05 (0.77–1.43) 0.76
CC 181 (32.91) 42 (32.81) 1 (Reference) 105 (31.44) 1 (Reference)
OR—adjusted odds ratio; CI—confidence interval; SNP—single nucleotide polymorphism.
Table 3. Distribution of the TMS6SF2 and MBOAT7 SNPs alleles and genotypes in alcohol and HCV




(n = 550) Alcoholic Cirrhosis (n = 171) HCV Induced Cirrhosis (n = 120)
n (%) n (%) aOR (95% CI) p n (%) aOR (95% CI) p
rs58542926 (TM6SF2)
T 41 (7.45) 14 (8.09) 1.13 (0.72–1.77) 0.60 9 (7.50) 0.96 (0.56–1.65) 0.88
C 509 (92.55) 157 (91.81) 111 (92.50)
TT 2 (0.36) 0 (0) 0.66 (0.03–13.86) 0.44 1 (0.83) 2.26 (0.20–25.21) 0.49
TC 77 (14.0) 28 (16.37) 1.21 (0.75–1.93) 0.44 15 (12.50) 0.88 (0.49–1.60) 0.68
CC 471 (85.64) 143 (83.63) 1 (Reference) 104 (86.67) 1 (Reference)
rs641738 (MBOAT7)
T 238 (43.27) 72 (42.11) 0.96 (0.75–1.23) 0.74 55 (45.83) 1.11 (0.83–1.46) 0.48
C 312 (56.73) 99 (57.89) 65 (54.17)
TT 108 (19.64) 31 (18.13) 0.91 (0.55–1.50) 0.72 23 (19.17) 1.17 (0.65–2.09) 0.60
TC 261 (47.45) 83 (48.54) 0.99 (0.68–1.47) 0.99 64 (53.33) 1.35 (0.85–2.13) 0.21
CC 181 (32.91) 57 (33.33) 1 (Reference) 33 (27.50) 1 (Reference)
OR—adjusted odds ratio; CI—confidence interval; SNP—single nucleotide polymorphism; HCV—hepatitis C virus.
2.3. Combined Analysis of PNPLA3 rs738409 and MBOAT7 or TM6SF2 SNP Genotypes
In this part of the study we used genotyping data from our previous study on PNPLA3 rs738409
and liver fibrosis/cirrhosis [11]. Tables 4 and 5 present the data for the combined PNPLA3 rs738409
and MBOAT7 or TM6SF2 genetic variants. This analysis showed no significant differences between
combined MBOAT7 and TM6SF2 SNPs and PNPLA3 risk genotypes.
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(TM6SF2) Cases (%) Controls (%) aOR (95% CI) p
CC CC 65 (87.83) 241 (87.31) 1.05 (0.48–2.29) 0.16
CC TC+TT 9 (12.16) 35 (12.68)
GC+GG CC 50 (92.59) 103 (82.4) 2.66 (0.87–8.16) 0.04





(TM6SF2) Cases (%) Controls (%) aOR (95% CI) p
CC CC 121 (85.82) 241 (87.32) 0.88 (0.49–1.59) 0.67
CC TC+TT 20 (14.18) 35 (12.68)
GC+GG CC 107 (83.59) 103 (82.40) 1.09 (0.57–2.10) 0.80





(TM6SF2) Cases (%) Controls (%) aOR (95% CI) p
CC CC 63 (86.30) 241 (87.32) 0.92 (0.43–1.95) 0.82
CC TC+TT 10 (13.70) 35 (12.68)
GC+GG CC 57 (80.28) 103 (82.40) 0.87 (0.41–1.83) 0.71





(TM6SF2) Cases (%) Controls (%) aOR (95% CI) p
CC CC 44 (93.62) 241 (87.32) 2.13 (0.63–7.23) 0.10
CC TC+TT 3 (6.38) 35 (12.68)
GC+GG CC 36 (83.72) 103 (82.40) 1.10 (0.43–2.79) 0.18
GC+GG TC+TT 7 (16.28) 22 (17.60)
OR—adjusted odds ratio; CI—confidence interval.





(MBOAT7) Cases (%) Controls (%) aOR (95% CI) p
CC CC 23 (31.51) 87 (31.52) 0.99 (0.57–1.741) 1.00
CC TC+TT 50 (68.49) 189 (68.48)
GC+GG CC 18 (32.73) 43 (34.40) 0.93 (0.47–1.82) 0.83





(MBOAT7) Cases (%) Controls (%) aOR (95% CI) p
CC CC 57 (40.43) 87 (31.52) 1.47 (0.97–2.25) 0.07
CC TC+TT 84 (59.57) 189 (68.48)
GC+GG CC 32 (25.00) 43 (34.40) 0.64 (0.37–1.09) 0.10
GC+GG TC+TT 96 (75.00) 82 (65.60)
Alcoholic Cirrhosis






(MBOAT7) Cases (%) Controls (%) aOR (95% CI) p
CC CC 31 (42.47) 87 (31.52) 1.60 (0.95–2.72) 0.08
CC TC+TT 42 (57.53) 189 (68.48)
GC+GG CC 18 (25.35) 43 (34.40) 0.65 (0.34–1.96) 0.19





(MBOAT7) Cases (%) Controls (%) aOR (95% CI) p
CC CC 18 (38.30) 87 (31.52) 1.35 (0.71–2.56) 0.36
CC TC+TT 29 (61.70) 189 (68.48)
GC+GG CC 8 (18.60) 43 (34.40) 0.44 (0.19–1.02) 0.02
GC+GG TC+TT 35 (81.40) 82 (65.60)
OR—adjusted odds ratio; CI—confidence interval.
3. Discussion
In the current study, we aimed to evaluate the associations between TM6SF2 rs58542926 and
MBOAT7 rs641738 genes polymorphisms and the risk of hepatic fibrosis and liver cirrhosis. Overall,
TM6SF2 and MBOAT7 SNPs were not linked with hepatic fibrosis and liver cirrhosis of different
etiology within our study. Additionally, we ran combined analysis to assess whether TM6SF2 and
MBOAT7 SNPs mediate the risk of liver fibrosis or liver cirrhosis in the presence of certain PNPLA3
genotypes. The effects of PNPLA3 have been well established in previous research, but we wanted to
see if the risk of liver fibrosis is changed by a certain combination of PNPLA3 and TM6SF2 or MBOAT7
genotypes. To the best of our knowledge, this is the first study of an Eastern European population that
assessed the impact of TM6SF2 rs58542926 and MBOAT7 rs641738 on developing liver injury.
TM6SF2 gene is important for the secretion of very-low density lipoprotein from hepatocytes.
Its reduced function leads to increased liver triglyceride and lipid droplet content which contributes
to NAFLD [17–19]. Genetic variations within TM6SF2 gene have been linked with a number of liver
conditions; however, reported results are varying in between. TM6SF2 rs58542926 was identified
as a modifier of hepatic fibrogenesis [13] and was associated with histological severity of steatosis,
increased hepatic inflammation and fibrosis [20,21]. Coppola et al. demonstrated that TM6SF2
rs58542926 is linked with development of severe liver steatosis in patients with chronic hepatitis C
(CHC), although no significant association between TM6SF2 and severe liver necro-inflammation or
fibrosis was found [16]. Further, in a later larger study, Milano et al. concluded that TM6SF2 rs58542926
not only had an impact on liver steatosis, but was also relevant in the development of severe fibrosis in
individuals with CHC [22]. Meanwhile, Sookoian et al. showed that rs58542926 has a modest effect on
NAFLD [23]. Moreover, TM6SF2 genotype did not impact histological features with biopsy-proven
NAFLD in Japanese patients [24]. To confirm the effect of TM6SF2 on fibrosis in NAFLD, CHC and
CHB patients, Eslam et al. used a large cohort of Caucasians and found that rs58542926 has more
influence on the serum metabolic profile and predisposed hepatic steatosis, rather than acting directly
on liver inflammation and fibrosis [25]. Another large cohort with genotype 1 HCV or with NAFLD
found no association between the TM6SF2 variant and hepatic fibrosis [26]. The results of our study
showed that direction for TM6SF2 rs58542926 between fibrosis and cirrhosis groups was different,
but the significance level was not reached and this genetic variant alone or combined with PNPLA3
risk genotype was not linked with liver fibrosis or cirrhosis.
The association of MBOAT7 rs641738 SNP with the entire spectrum of NAFLD in individuals of
European descent was first reported by Mancina et al. [27]. The same MBOAT7 genetic variant was
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not associated with hepatic steatosis, but significantly linked to hepatic fibrosis by Krawczyk M. and
colleagues [15]. In an Asian population, MBOAT7 rs641738 was not linked with risk of developing
NAFLD [21]. Yet another study found no association between rs641738 and liver steatosis, but an
association with hepatic inflammation and fibrosis in CHC was detected [14]. Nevertheless, no recent
studies were conducted to evaluate the significance of this genotype on hepatic fibrosis or cirrhosis
of different etiology. Varying findings of different studies clearly show that the final outcome of
chronic liver injury may have a different effect from genetic factors in different populations. Within
our study MBOAT7 locus rs641738 was not linked with liver fibrosis or cirrhosis. When combining
different genotypes of this SNP with a well know PNPLA3 rs738409 variant no significant differences
were observed.
There are certain limitations associated with the design of our study that need to be acknowledged.
The major limitation of our study is related to etiological heterogeneity of liver cirrhosis cohort and not
a large number of patients within the subgroup analysis. Most of our patients in the liver fibrosis group
had HCV induced fibrosis. Moreover, relatively small sample sizes within combined PNPLA3 SNP
sub-analysis needs further re-evaluation in larger well-defined cohorts in order to evaluate observed
synergistic effects of different genetic variations.
4. Materials and Methods
4.1. Patients
The TM6SF2 rs58542926 and MBOAT7 rs641738 genotyping study included 1012 individuals
(550 controls, 334 patients with liver cirrhosis and 128 patients with liver fibrosis). For combined
analyses of carriers of PNPLA3 rs738409 risk genotype, we used data from our previous study with the
same cohort [11] and included 798 individuals (401 controls and 269 patients with liver cirrhosis and 128
patients with liver fibrosis). Patients with liver cirrhosis and hepatic fibrosis were recruited during the
period 2012–2017. Diagnosis of liver cirrhosis was established by standard clinical features, laboratory
tests, and radiological imaging. Hepatic fibrosis was diagnosed based on histological evaluation of
liver biopsy specimens. Liver fibrosis group consisted of the patients that had stage I to stage III fibrosis
in histological evaluation according to the METAVIR score [28]. All individuals that had fibrosis stage
IV according to Metavir score were transferred to liver cirrhosis group. Control samples came from
our previous genotyping study on the prevalence of HFE mutations in the Lithuanian population and
included 550 voluntary, unrelated Lithuanian blood donors [29]. The genotyping was conducted at the
Institute for Digestive Research at Lithuanian University of Health Sciences Hospital. The study was
carried out in line with the 1975 Declaration of Helsinki (6th revision, 2008). All patients and controls
have written an informed consent to participate in this study. The study was approved by Regional
Kaunas Ethics Committee (Protocol No. BE-10-2, approval date: 08 March 2011).
4.2. Genotyping
Genomic DNA from samples was isolated from whole blood mononuclear cells using a salting-out
method and stored at −20 ◦C until analysis, as described previously [30]. TM6SF2 rs58542926
and MBOAT7 rs641738 SNPs were genotyped by real-time PCR (RT-PCR), using TaqMan® allelic
discrimination assays with a 7500TM Fast real-time PCR system (Life Technologies, Carlsbad,
CA, USA).
4.3. Statistical Analysis
TM6SF2 and MBOAT7 alleles and genotypes frequencies between cases and controls were
compared by Pearson’s goodness-of-fit χ2 and Fisher exact tests. Associations between control and
cases groups with SNP alleles and genotypes were calculated using logistic regression analysis with
adjustment for age and sex. Table 2 summarizes the adjusted odds ratios (aORs) and 95% confidence
intervals (CI). Age between groups was compared using analysis of variance (ANOVA). Gender
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distributions were compared using the χ2 tests. For additional analysis, we divided the cohort in two
groups with respect to PNPLA3 rs738409 genotypes. p-value was adjusted for multiple comparisons
and the value of <0.025 (0.05/2) was considered to be statistically significant. Statistical analysis of the
genotyping data was performed using PLINK software version 1.07 [31].
5. Conclusions
In conclusion, TM6SF2 rs58542926 as well as MBOAT7 rs641738 were not linked to hepatic fibrosis,
alcohol or hepatitis C virus induced liver cirrhosis in an Eastern European population. These genetic
variations also did not mediate the effect of PNPLA3 rs738409 SNP on the development of liver fibrosis
or liver cirrhosis.
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11. Kupcinskas, J.; Valantiene, I.; Varkalaitė, G.; Steponaitiene, R.; Skieceviciene, J.; Sumskiene, J.; Petrenkiene, V.;
Kondrackiene, J.; Kiudelis, G.; Lammert, F.; et al. PNPLA3 and RNF7 Gene Variants are Associated with the
Risk of Developing Liver Fibrosis and Cirrhosis in an Eastern European Population. J. Gastrointest. Liver
Dis. JGLD 2017, 26, 37–43.
Int. J. Mol. Sci. 2019, 20, 1277 8 of 9
12. Buch, S.; Stickel, F.; Trépo, E.; Way, M.; Herrmann, A.; Nischalke, H.D.; Brosch, M.; Rosendahl, J.; Berg, T.;
Ridinger, M.; et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7
as risk loci for alcohol-related cirrhosis. Nat. Genet. 2015, 47, 1443–1448. [CrossRef]
13. Liu, Y.-L.; Reeves, H.L.; Burt, A.D.; Tiniakos, D.; McPherson, S.; Leathart, J.B.S.; Allison, M.E.D.;
Alexander, G.J.; Piguet, A.-C.; Anty, R.; et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in
patients with non-alcoholic fatty liver disease. Nat. Commun. 2014, 5, 4309. [CrossRef]
14. Thabet, K.; Asimakopoulos, A.; Shojaei, M.; Romero-Gomez, M.; Mangia, A.; Irving, W.L.; Berg, T.; Dore, G.J.;
Grønbæk, H.; Sheridan, D.; et al. MBOAT7 rs641738 increases risk of liver inflammation and transition to
fibrosis in chronic hepatitis C. Nat. Commun. 2016, 7, 12757. [CrossRef]
15. Krawczyk, M.; Rau, M.; Schattenberg, J.M.; Bantel, H.; Pathil, A.; Demir, M.; Kluwe, J.; Boettler, T.;
Lammert, F.; Geier, A.; et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7
rs641738 variants on NAFLD severity: A multicenter biopsy-based study1. J. Lipid Res. 2017, 58, 247–255.
[CrossRef]
16. Coppola, N.; Rosa, Z.; Cirillo, G.; Stanzione, M.; Macera, M.; Boemio, A.; Grandone, A.; Pisaturo, M.;
Marrone, A.; Adinolfi, L.E.; et al. TM6SF2 E167K variant is associated with severe steatosis in chronic
hepatitis C, regardless of PNPLA3 polymorphism. Liver Int. Off. J. Int. Assoc. Study Liver 2015, 35, 1959–1963.
[CrossRef]
17. Seko, Y.; Yamaguchi, K.; Itoh, Y. The genetic backgrounds in nonalcoholic fatty liver disease. Clin. J.
Gastroenterol. 2018, 11, 97–102. [CrossRef]
18. Mahdessian, H.; Taxiarchis, A.; Popov, S.; Silveira, A.; Franco-Cereceda, A.; Hamsten, A.; Eriksson, P.;
Hooft, F.V. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid
droplet content. Proc. Natl. Acad. Sci. USA 2014, 111, 8913–8918. [CrossRef]
19. Kozlitina, J.; Smagris, E.; Stender, S.; Nordestgaard, B.G.; Zhou, H.H.; Tybjærg-Hansen, A.; Vogt, T.F.;
Hobbs, H.H.; Cohen, J.C. Exome-wide association study identifies a TM6SF2 variant that confers
susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2014, 46, 352–356. [CrossRef]
20. Dongiovanni, P.; Petta, S.; Maglio, C.; Fracanzani, A.L.; Pipitone, R.M.; Mozzi, E.; Motta, B.M.; Kaminska, D.;
Rametta, R.; Grimaudo, S.; et al. Transmembrane 6 superfamily member 2 gene variant disentangles
nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015, 61, 506–514. [CrossRef]
21. Koo, B.K.; Joo, S.K.; Kim, D.; Bae, J.M.; Park, J.H.; Kim, J.H.; Kim, W. Additive effects of PNPLA3 and TM6SF2
on the histological severity of non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2018, 33, 1277–1285.
[CrossRef]
22. Milano, M.; Aghemo, A.; Mancina, R.M.; Fischer, J.; Dongiovanni, P.; De Nicola, S.; Fracanzani, A.L.;
D’Ambrosio, R.; Maggioni, M.; De Francesco, R.; et al. Transmembrane 6 superfamily member 2 gene E167K
variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology 2015, 62, 111–117.
[CrossRef]
23. Sookoian, S.; Castaño, G.O.; Scian, R.; Mallardi, P.; Gianotti, T.F.; Martino, J.S.; Pirola, C.J.; Burgueño, A.L.
Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease
and histological disease severity. Hepatology 2015, 61, 515–525. [CrossRef]
24. Akuta, N.; Kawamura, Y.; Arase, Y.; Suzuki, F.; Sezaki, H.; Hosaka, T.; Kobayashi, M.; Kobayashi, M.;
Saitoh, S.; Suzuki, Y.; et al. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological
Features of Nonalcoholic Fatty Liver Disease in Japan. Gut Liver 2016, 10, 437–445. [CrossRef]
25. Eslam, M.; Mangia, A.; Berg, T.; Chan, H.L.Y.; Irving, W.L.; Dore, G.J.; Abate, M.L.; Bugianesi, E.; Adams, L.A.;
Najim, M.A.; et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver
disease phenotypes. Hepatology 2016, 64, 34–46. [CrossRef]
26. Petta, S.; Maida, M.F.; Grimaudo, S.; Pipitone, R.M.; Macaluso, F.S.; Cabibi, D.; Camma’, C.; Di Marco, V.;
Sferrazza, S.; Craxi, A. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of
patients with genotype 1 chronic hepatitis C. Liver Int. 2016, 36, 198–204. [CrossRef]
27. Mancina, R.M.; Dongiovanni, P.; Petta, S.; Pingitore, P.; Meroni, M.; Rametta, R.; Borén, J.; Montalcini, T.;
Pujia, A.; Wiklund, O.; et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty
Liver Disease in Individuals of European Descent. Gastroenterology 2016, 150, 1219–1230.e6. [CrossRef]
28. Bedossa, P.; Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996, 24,
289–293. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 1277 9 of 9
29. Kucinskas, L.; Juzenas, S.; Sventoraityte, J.; Cedaviciute, R.; Vitkauskiene, A.; Kalibatas, V.; Kondrackienė, J.;
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